Gupta G, Yakubu I, Zhang Y, et al. - Previously, hepatitis C virus (HCV) transmission of 13% was noted in D+/R− transplants (infected donors to uninfected kidney transplant recipients) with 2- to 4-day pangenotypic sofosbuvir/velpatasvir perioperative prophylaxis, where one patient with HCV transmission was a nonresponder to first-line full-course direct-acting antiviral drug, researchers here present new observations with a 7-day preventive protocol (N = 50), as well as cumulative management and outcome data on all HCV D+/R− transplants (N = 102). HCV transmission occurred in nine patients (9/102), and the 7-day group (2/50) showed a significant decline vs 2- to 4-day prophylaxis (7/52). A 1:1 matched analysis (N = 102) was conducted with contemporary HCV D−/R− transplants (controls), which revealed significantly shorter pretransplant wait time for D+/R− vs D−/R−, but no differences were found in infections, rejection, development of de novo donor-specific antibody, or transplant results up to 6 months of transplant.